Category: Regions

ViGeneron Signs Gene Therapy Strategic Collaboration and Option Agreement with Regeneron for One Inherited Retinal Disease Target
April 6, 2022 Off

ViGeneron Signs Gene Therapy Strategic Collaboration and Option Agreement with Regeneron for One Inherited Retinal Disease Target

By Author

ViGeneron GmbH, a next-generation gene therapy company, has announced a target-specific strategic collaboration and option agreement with Regeneron Pharmaceuticals Inc. (Regeneron) to develop and commercialize a gene therapy product based on ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to treat an inherited retinal disease (IRD).

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1 Expression ≥ 1%
April 5, 2022 Off

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1 Expression ≥ 1%

By Author

The European Commission (EC) has approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) with tumor cell PD-L1 expression ≥ 1%.

Novartis Presents New Four-Year Data on Efficacy and Safety of Kesimpta (ofatumumab) in People Living with Relapsing Multiple Sclerosis
April 5, 2022 Off

Novartis Presents New Four-Year Data on Efficacy and Safety of Kesimpta (ofatumumab) in People Living with Relapsing Multiple Sclerosis

By Author

Novartis has announced new long-term data from the Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension that demonstrated long-term efficacy and safety of Kesimpta (ofatumumab), with continued reduced risk of disability worsening, for people living with relapsing multiple sclerosis following up to four years of treatment.

AbbVie and We Are Pioneer Group Launch Golden Ticket Programme to Help UK Life Science Start-ups Accelerate the Delivery of Life-Changing Innovations to Patients
April 4, 2022 Off

AbbVie and We Are Pioneer Group Launch Golden Ticket Programme to Help UK Life Science Start-ups Accelerate the Delivery of Life-Changing Innovations to Patients

By Dino Mustafić

AbbVie, the global research-driven biopharmaceutical company and We Are Pioneer Group (WAPG), Europe’s largest ecosystem provider for science and innovation businesses, to support the thriving UK life sciences start-up community, has launched a programme designed to help early-stage life science companies commercialise drug discovery and gain access to crucial research space.